PA
AERI

Perceptive Advisors’s Aerie Pharmaceuticals AERI Stock Holding History

Perceptive Advisors’s Portfolio AERI Stock Details AERI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-50,000
Closed -$2.27M – 169
2017
Q1 		$2.27M Hold
50,000
– – 0.13% 79
2016
Q4 		$1.89M Sell
50,000
-356,771
-88% -$13.5M 0.13% 81
2016
Q3 		$15.4M Buy
+406,771
New +$8.97M 0.99% 24
2014
Q4 		– Sell
-1,121,951
Closed -$5.44M – 171
2014
Q3 		$5.44M Hold
1,121,951
– – 0.55% 44
2014
Q2 		$4.2M Buy
1,121,951
+910,433
+430% +$15.8M 0.41% 48
2014
Q1 		$4.48M Sell
211,518
-88,482
-29% -$1.79M 0.47% 50
2013
Q4 		$5.39M Buy
+300,000
New +$3.91M 0.65% 35

Other funds holding AERI

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Perceptive Advisors's AERI Position: Q2 2017 in Review

Perceptive Advisors sold out of Aerie Pharmaceuticals (AERI) in Q2 2017, closing a stake of 50,000 shares — an estimated $2.27M sold.

Perceptive Advisors first reported a position in AERI in Q4 2013 and held it in 7 quarters. The position peaked at $15.4M in Q3 2016. 172 funds tracked by Wall St. Rank hold AERI as of Q2 2017.

  • Perceptive Advisors reported no remaining Aerie Pharmaceuticals position as of Q2 2017 after selling out during the quarter.
  • Perceptive Advisors sold 50,000 Aerie Pharmaceuticals shares in Q2 2017, an estimated $2.27M.
  • Perceptive Advisors first reported a position in Aerie Pharmaceuticals in Q4 2013 and held it in 7 quarters.
  • Perceptive Advisors's Aerie Pharmaceuticals position peaked at $15.4M in Q3 2016.
  • 172 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q2 2017.

Based on Perceptive Advisors's 13F filing for Q2 2017, filed 14 Aug 2017.